Gabapentin Versus Loratadine in Uremic Pruritus

• Status: Completed
• Trial end date: 2022-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare the efficacy of gabapentin with loratadine in reducing the severity of uremic pruritus in patients of chronic kidney disease and to compare the side effects of both drugs. The main questions it aims to answer are:

• Which drug (gabapentin versus loratadine) is more effective in reducing the severity of uremic pruritus?

• Which drug (gabapentin versus loratadine) has fewer side effects?

Participants were divided into two groups.Group A received loratadine 10mg daily and group B received gabapentin 100mg daily. Both groups were given treatment for 4 weeks.

• Participants were asked to grade the severity of pruritus on a numerical rating scale and also answer the Dermatology Life Quality Index Questionnaire (DLQI)

• Participants were also asked to report any side effects, if occurred.

Researchers compared both groups with regards to improvement in pruritus severity, DLQI score and side effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Edward Medical University
• Treatments: Gabapentin; Loratadine

Criteria

Inclusion Criteria:

• Chronic kidney disease, stage 3 and above, irrespective of dialysis status

• Persistent pruritus, of moderate to very severe intensity (≥ 4 points on numerical rating scale), occurring at least 3 times a week, for at least 2 weeks, in a 1-month period.

Exclusion Criteria:

• Chronic skin conditions such as eczema, psoriasis, etc.

• Pruritus due to any other cause, such as metabolic abnormalities, liver disease, etc.

• History of drugs causing pruritus such as opioids, etc

• Pregnant patients

• Preceding history of allergy to either gabapentin or loratadine.